Siponimod Stabilizes Physical Disability Scores in People Living With Secondary Progressive Multiple Sclerosis After 2 Years of Treatment: Analysis From the Novartis Global Managed Access Program

Ocrelizumab and Cladribine had similar EDSS stability and safety profile in patients with highly active multiple sclerosis

Evaluating the Effect of Disease Duration in High Efficacy Versus Mid Efficacy Disease Modifying Therapies: Could This Help in Deciding When to De-escalate?